Cancer is a major public health issue that affects people all over the world, and it is one of the leading causes of morbidity and mortality in both children and adults. Malignant tumours are fatal because they grow uncontrollably within normal tissues, causing harm and functional impairment. The malignant phenotype of cancers is characterized by deficiencies in cell growth control, tumour cell resistance to apoptosis, tumour cell ability to penetrate host tissues and spread to distant areas, and tumour evasion of host immune defence mechanisms. The higher prevalence of certain types of cancers in immunocompromised experimental animals and humans has established the existence of immune surveillance. It is now evident that many cancers elicit responses from the innate and adaptive immune systems, and tumour immunologists are working to harness these responses to precisely eliminate tumours. Tumor immunology is the study of the connection between immune function and tumour cells, which is critical for understanding tumour rejection and progression mechanisms. The immunological systems involved in cancer progression, which include tissue-resident and blood-derived cells, are extremely complex.
Title : Antibody proteases as translational biomarkers, targets, and biocatalysts of the next generation step as applicable for design driven precision medical practice
Sergey Victorovich Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through biodesign inspired and immunology related translational applications to secure human healthcare and biosafety
Sergey Victorovich Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation